AMGN - Amgen Inc
One of the original biotech pioneers, leveraging biologics expertise to build a portfolio in cardiovascular, oncology, and inflammation therapies.
Finlify Score
48.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$350.53
-1.31%
52W Range
$267.83 - $391.29
Market Cap
$181.8B
-1.3%Compared to previous day
2026 Q1 Revenue
$8.6B
-12.6%Changes from last reporting quarter
2026 Q1 EPS
$3.34
Diluted shares
Analyst Rating
44 analysts in latest ratings feed
RSI
61.3
40-70 moderate
2Y Range Position
70%
-10.4% from high / +38.4% from low
Beta
0.41
Relative to market benchmark
MACD
2.09
MACD line 3.35 / signal line 1.26
Fundamental Trend
Growth 43.0Financial Health
Quality 80.8Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD48.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $8.6B-12.6% | $9.9B+3.2% | $9.6B+4.1% | $9.2B+12.6% |
| Gross Profit | - | - | - | - |
| Operating Income | $2.7B-2.0% | $2.7B+7.7% | $2.5B-4.9% | $2.7B+125.5% |
| Net Income | $1.8B+36.5% | $1.3B-58.6% | $3.2B+124.6% | $1.4B-17.2% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
Finlify's signal for Amgen Inc (AMGN) on 2026-06-12 is HOLD, supported by a Finlify Score of 49.9/100, which suggests a neutral outlook based on the quantitative factors.
Technical
The asset's Relative Strength score of 45.8/100 and Accumulation / Volume score of 28.4/100 appear below average, potentially indicating limited buying pressure. However, AMGN has shown a positive 20-day return of 5.6% and its RSI(14) at 61.9 suggests some recent positive momentum, though it is approaching levels that may indicate it is becoming overbought.
Fundamentals
While Amgen demonstrates strong Financial Quality with a score of 80.8/100, its Fundamental Trend score of 43.0/100 appears below average. The company's valuation multiples, such as a P/E of 24.8x and P/B of 20.4x, may suggest a premium valuation. AMGN also offers a dividend yield of 2.85% and has a low beta of 0.4, indicating relatively lower volatility.
Macro Context
In a macro environment with elevated inflation, indicated by CPI YoY at 4.3% and Core PCE YoY at 3.3%, and a 10-year Treasury yield at 4.5%, AMGN's low beta of 0.4 may offer some defensive characteristics. However, higher interest rates could potentially impact valuations for growth-oriented sectors, even for a more established biotechnology company.
Key Risks
- The low Accumulation / Volume score of 28.4/100 suggests a potential lack of strong buying interest.
- A Fundamental Trend score of 43.0/100 indicates that underlying business momentum may be weaker than desired.
- Valuation multiples, including a P/E of 24.8x and P/B of 20.4x, appear somewhat elevated, which could limit future upside.